Aug. 17 at 3:01 PM
$ARGX is sharply higher today after argenx reported positive Phase 3 ALKIVIA data on August 17 for VYVGART Hytrulo in autoimmune myositis. The combined IMNM/DM population met the primary endpoint, showing a 15.4-point greater improvement in TIS versus placebo. IMNM also reached statistical significance on its own, while the smaller DM subgroup showed a similar numerical benefit but missed significance.
The market is treating this as a meaningful expansion opportunity for the VYVGART franchise, with shares up roughly 17% intraday. I think the key next question is regulatory: how quickly can argenx turn the IMNM result into an approval path?
Not financial advice. Do your own research.
